CJC-1295 + Ipamorelin: the growth hormone stack explained
May 10
For research purposes only. CJC-1295 and Ipamorelin are classified as research peptides and are not approved for human use by any pharmaceutical agency. All information in this article is strictly informative and scientific.
CJC-1295 and Ipamorelin are often combined in what is called a GHRH stack — one of the most studied peptide combinations in preclinical research on the growth hormone axis. Individually, they stimulate different parts of the release mechanism; together they create a synergistic effect reminiscent of the body’s natural pulsating growth hormone secretion.
Below is a quick comparison of the most important parameters of the two peptides.
| Parameter | CJC-1295 | Ipamorelin |
|---|
|Mechanism|GHRH analog|Ghrelin mimetic (GHRP)|
|Half-life|~6–8 days (DAC variant)|~2 hours|
|Typical dose per injection|100–300 µg|200–300 µg|
|Selectivity|Moderate — affects IGF-1 broadly|High — minimal cortisol/prolactin effect|
|Most common side effects|Fluid accumulation, tingling sensation|Mild flushing, hunger immediately after dose|
|Regulatory status|Research peptide, not approved|Research peptide, not approved|
The cjc-1295 ipamorelin combination is particularly interesting because the two peptides activate the growth hormone axis via completely separate receptors, minimizing receptor desensitization and theoretically providing a more physiological release pattern.
How CJC-1295 works as a GHRH analog
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH), a 44 amino acid neuropeptide hormone produced in the nucleus arcuatus of the hypothalamus. The most widely used research variant—CJC-1295 with DAC (Drug Affinity Complex)—covalently binds to albumin in the blood, extending the half-life from a few minutes (natural GHRH) to an estimated 6–8 days.
Early preclinical data, including studies published in the Journal of Clinical Endocrinology & Metabolism, showed that single doses of CJC-1295 in healthy adults increased mean GH levels by 2–10 times baseline over a 6-day period. IGF-1 levels rose by 1.5–3-fold and remained elevated for up to 28 days after repeated dosing.
An important distinction in cjc 1295 dosage applies precisely to the DAC variant versus CJC-1295 without DAC (sometimes called Mod GRF 1-29). Without the DAC modification, the half-life is more similar to natural GHRH — approximately 30 minutes — and is better suited for pulsatile administration near bedtime.
What the IGF-1 increase actually means in research
IGF-1 (Insulin-like Growth Factor 1) is the primary mediator of growth hormone’s anabolic effects and is mainly produced in the liver in response to GH signaling. In animal models, elevated IGF-1 levels have been linked to increased protein synthesis rates, improved bone mineral density, and accelerated wound healing — mechanisms that make the peptide interesting for aging research and recovery studies.
However, it is crucial to understand that these effects are primarily documented in rodent models and controlled human studies with strict inclusion and exclusion criteria. Extrapolation to clinical practice or exercise protocols lacks robust human data.
Ipamorelin as a selective GHRP in the growth hormone stack
Ipamorelin belongs to the Growth Hormone Releasing Peptides (GHRP) family and acts as a ghrelin mimetic — it binds to the GHS-R1a receptor (ghrelin receptor) in the pituitary gland and directly stimulates GH release. What sets Ipamorelin apart from older GHRPs such as GHRP-2 and GHRP-6 is its exceptional selectivity.
Ipamorelin side effects are generally milder than other peptides in the same class. In Phase I/II clinical trials conducted by Novo Nordisk in the early 2000s, no statistically significant increase in cortisol, prolactin, or ACTH was observed at therapeutic doses — a problem that limits the use of GHRP-2 and GHRP-6 in research. The only consistently reported acute effect is a transient feeling of hunger 15–30 minutes after injection, linked to the role of the ghrelin receptor in appetite regulation.
The half-life of approximately 2 hours means that Ipamorelin creates distinct GH pulses rather than a continuous basal level increase. Research suggests that pulsatile GH secretion — which resembles the body’s natural pattern — preserves receptor sensitivity better over time compared to continuous stimulation.
Ipamorelin in combination — why the synergy occurs
When Ipamorelin is combined with a GHRH analog, the two complementary pathways of GH release are activated simultaneously. GHRH increases the size of the GH pulse by amplifying the basal response of the somatotropic cells; GHRP peptides such as Ipamorelin, on the other hand, increase heart rate and block somatostatin — the inhibitory hormone that normally “slows down” GH secretion.
The result is a GH pulse that in preclinical models can be 2-5 times greater than either peptide generates alone. It is this phenomenon that makes the growth hormone peptide stack protocol an active area of research in gerontology and metabolic medicine.
Dosing and administration protocol in research
The standard protocol in most preclinical and exploratory human studies involves subcutaneous injection of both peptides simultaneously, usually 30–60 minutes before bedtime to coincide with the body’s natural nocturnal GH peak. The dose ranges below taken from published research protocols should be treated as reference points, not clinical recommendations.
-
CJC-1295 without DAC (Mod GRF 1-29): 100–300 µg per injection, 1–3 times daily
-
CJC-1295 with DAC: 1–2 mg per week, administered 1–2 times per week
-
Ipamorelin: 200–300 µg per injection, combined with each CJC dose
-
Cycle length in studies: 8–16 weeks with follow-up measurements of IGF-1 every 4 weeks
-
Time of injection: Fasting or low glycemic state recommended — insulin inhibits GH release and reduces the effect of the peptides by an estimated 30-50%
The Ghrh stack protocol requires careful preparation: peptide preparations are usually reconstituted in bacteriostatic water and stored at 2–8°C. Stability studies indicate that reconstituted solutions retain >95% potency for 28–30 days when properly stored.
An often overlooked aspect of dosing is timing relative to other hormonal factors. Cortisol antagonizes GH signaling; morning doses below natural cortisol peak are thus suboptimal from a purely pharmacodynamic perspective, which explains the preference for evening administration in research protocols.
Regulatory status and legal classification
Neither CJC-1295 nor Ipamorelin are approved medicines in Sweden, the EU or the USA. They are classified by the Swedish Medicines Agency and the FDA as “research chemicals” or investigational peptides — substances available for laboratory use and preclinical research, but without market approval for human use.
From a practical regulatory perspective, this has several important consequences. In organized sport, both peptides are classified as prohibited by WADA under the category Peptide Hormones, Growth Factors and Related Substances (S2) — doping in controlled competitions. For Swedish practitioners under the RF’s rules, the same prohibition applies.
The manufacture and sale of these peptides falls into a legal gray area in Sweden. Import for “personal use” is formally prohibited without a doctor’s prescription, but enforcement varies. The fact that the substances are not classified as narcotics in Sweden means that the legal situation is different than, for example, for anabolic steroids — but this does not mean that use is legal or medically proven to be safe.
Clinical research is ongoing. Ipamorelin was tested in phase II by Novo Nordisk for postoperative bowel motility disorders. CJC-1295 has been studied in controlled human studies in middle-aged subjects with GH insufficiency. However, none of these indications have led to market approval, and off-label use occurs entirely outside of controlled medical contexts.
Frequently asked questions about CJC-1295 and Ipamorelin
How quickly are effects seen in research studies?
In controlled human studies, GH pulse response is often measured acutely (within 1–3 h of injection) and IGF-1 changes after 2–4 weeks of continuous dosing. Subjective parameters such as sleep quality and recovery are often reported within 2–3 weeks in open observational studies, but lack of blinding makes these data difficult to interpret.
Is the CJC-1295 with DAC better than without DAC?
The DAC variant provides a stable, long-lasting GH elevation similar to basal IGF-1 stimulation rather than physiological pulses. The variant without DAC (Mod GRF 1-29) produces clearer pulses that better imitate natural secretion. Which variant is more beneficial depends on the goals and measurement parameters of the specific research protocol.
Can Ipamorelin be taken without CJC-1295?
Ipamorelin acts as an independent GHRP and generates GH release even without a GHRH analogue. In research, it is sometimes used in isolation to study the role of the ghrelin receptor. However, the effect size of GH pulses is consistently lower without the GHRH component, which is why combination protocols dominate the literature.
Which side effects are documented in human studies?
The most consistently reported effects with CJC-1295 include transient fluid retention, tingling in the extremities, and fatigue during the first few days of treatment. Ipamorelin side effects primarily include transient hunger, mild flush and sometimes mild headache. No serious cardiovascular or metabolic events were reported in published phase I/II studies at therapeutic doses.
Do these peptides affect cortisol and insulin sensitivity?
CJC-1295 minimally affects cortisol in published studies. Ipamorelin is specifically selective and does not increase cortisol or prolactin at recommended doses — unlike GHRP-2 and GHRP-6. However, GH elevation may transiently reduce insulin sensitivity, which is a known physiological effect of GH and warrants attention in metabolic research.
How does the GHRH stack differ from exogenous growth hormone?
Exogenous GH (such as recombinant HGH) replaces the body’s endogenous production and can lead to pituitary suppression with prolonged use. GHRH stacks instead stimulate the pituitary’s own somatotropic cells and preserve the pulsatile secretion profile. Theoretically, this means a lower risk of shoulder suppression, but long-term safety data on healthy individuals is lacking.
.entry-content